14822 Federal Register / Vol. 72, No. 60 / Thursday, March 29, 2007 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Workshop to Discuss Development of 

a Women’s Health Information Sharing 

Network 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of meeting. 

The Food and Drug Administration’s 

(FDA’s) Office of Women’s Health is 

announcing the following meeting: 

‘‘Workshop to Develop a Women’s 

Health Information Sharing Network’’ to 

discuss opportunities for national 

organizations to share information about 

their women’s health education 

activities. There will be two meetings. 

One will focus on Hispanic/Latina 

populations, and the other will focus on 

all other communities. Representatives 

of national community-based 

organizations are invited. A continental 

breakfast will be provided. 

Date and Time: The meetings will be 

held on April 12 and 13, 2007, from 

8:30 am to 11:30 am. 

Location: The meetings will be held at 

AARP, 601 East St., NW., Washington, 

DC 20049. 

Contact: Susana Perry, FDA Office of 

Women’s Health (HF–8), Food and Drug 

Administration, 5600 Fishers Lane, rm. 

16–65, Rockville, MD 20857, 301–827–

0350, FAX: 301–827–9194, e-mail: 

susana.perry@fda.hhs.gov. 

Registration: There is no fee, but preregistration is required for security 

purposes by AARP. Seating is limited to 

20 participants for each meeting. 

If you need special accommodations 

due to a disability, please contact 

Susana Perry at least 7 days in advance 

(by April 6, 2007). 

Dated: March 23, 2007. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

[FR Doc. 07–1546 Filed 3–27–07; 8:50 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Survey of Complementary and 

Alternative Medicine Use by United 

States Cancer Patients Comment 

Period 

AGENCY: National Cancer Institute (NCI), 

National Institutes of Health (NIH), 

Department of Health and Human 

Services (HHS). 

ACTION: Request for public comment. 

SUMMARY: In compliance with the 

provisions of section 3506(c)(2)(A) of 

the Paperwork Reduction Act of 1995, 

for opportunity for public comments on 

proposed data collection projects, the 

National Institutes of Health (NIH), 

National Cancer Institute (NCI) will 

publish periodic summaries of proposed 

projects to be submitted to the Office of 

Management and Budget (OMB) for 

review and approval. 

DATES: The National Survey of Cancer 

CAM Researchers’ Recommendations 

public comment period will run from 

May 1, 2007 to June 30, 2007. 

ADDRESSES: Comments may be 

submitted electronically at http:// 

www.cancer.gov/cam. 

Background: Title: National Survey of 

Complementary and Alternative 

Medicine Use by United States Cancer 

Patients. Type of Information Collection 

Request: New. Need and Use of 

Information Collection: There have been 

many regional surveys conducted about 

the use of CAM by cancer patients, but 

only one national survey which was 

published in 1992 The NCI is seeking to 

determine whether it should make an 

investment in the gathering of current 

nationally representative data on cancer 

patients’ use of CAM. 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(a) Whether nationally representative 

data should be obtained on CAM use by 

U.S. cancer patients; (b) the type of data 

about CAM use by U.S. cancer patients 

which should be considered high 

priority; (c) whether international data 

on CAM use by cancer patients should 

be collected; and (d) appropriate uses 

for any data on CAM use by cancer 

patients that is collected. 

Dated: February 28, 2007. 

Shea Buckman, 

NCI OCCAM Communications and Outreach 

Manager, National Institutes of Health. 

[FR Doc. E7–5832 Filed 3–28–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute, Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung 

and Blood Institute Special Emphasis Panel, 

Research Project in Drug Therapy. 

Date: April 26, 2007. 

Time: 10:30 a.m. to 12:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person:: Mark Roltsch, PhD, 

Scientific Review Administrator, Review 

Branch/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7192, Bethesda, MD 20892–7924, 301–435–

0287, roltschm@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Disease Research; 93.839, Blood Diseases and 

Resources Research, National Institutes of 

Health, HHS) 

Dated: March 22, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1548 Filed 3–28–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 


jlentini on PROD1PC65 with NOTICES